Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination

  1. Lucas Bochnia-Bueno
  2. Sergio Monteiro De Almeida
  3. Sonia Mara Raboni
  4. Douglas Adamoski
  5. Ludmilla Louise Moreira Amadeu
  6. Suzana Carstensen
  7. Meri Bordignon Nogueira

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.diagmicrobio.2021.115597
  2. Version published to 10.1101/2021.05.20.21255825v3 on medRxiv
  3. Version published to 10.1101/2021.05.20.21255825v2 on medRxiv
  4. ScreenIT

    SciScore for 10.1101/2021.05.20.21255825: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: The Institutional Ethical Committee approved the study (CAAE: 31687620.2.0000.0096), and all participants signed their consent.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    For all serum samples, assays used the Chemiluminescent Microparticle Immunoassay (CMIA) Architect-I System for anti-nucleocapsid protein (anti-N) IgG (Abbott, Sligo, Ireland).
    Abbott
    suggested: (Abbott, RRID:SCR_010477)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    The present study has some limitations: the humoral immunity was studied semi-quantitatively, there was no quantification and titration of anti-SARS-CoV-2 antibodies, and no testing for neutralizing antibodies. The total number of participants was small, and immunosuppressed comorbidities were low in number and had diverse etiologies. More studies are needed to elucidate the vaccine response in these specific groups. However, this is the first study to evaluate the dynamics of IgG production after CoronaVac immunization in the community. The results of seroconversion have shown the importance of two doses for this vaccine as, until the second dose was applied, there was no change in the production of N-protein IgG, as previously described by Zhang et al. (2021) in phase I/II tests for this vaccine, with the antibody response detectable just 14 days after the second dose. The second vaccine dose is important for several types of vaccines, including mRNA vaccines, as described by Dörschug et al. (2021), resulting in a significant increase in antibody levels. Therefore, with SARS-CoV-2, there would be no difference at this point. In conclusion, significant antibody production was observed 40 days after the first CoronaVac dose in the large majority of study participants, independent of comorbidities. The anti-N protein and anti-S1 protein antibody responses of participants without prior SARS-CoV-2 infection were comparable with those of the previously infected group, in which th...

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  5. Version published to 10.1101/2021.05.20.21255825v1 on medRxiv